MedinCell S.A. (EPA:MEDCL)
France · Delayed Price · Currency is EUR 22.56
-0.52 (-2.25%)
At close: Jan 30, 2026
MedinCell Employees
MedinCell had 145 employees as of September 30, 2025. The number of employees increased by 14 or 10.69% since the number was reported on March 31, 2025.
Employees
145
Change
14
Growth
10.69%
Revenue / Employee
€223,717
Profits / Employee
€137,572
Market Cap
746.80M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 145 | 14 | 10.69% |
| Mar 31, 2025 | 131 | -3 | -2.24% |
| Mar 31, 2024 | 134 | 3 | 2.29% |
| Mar 31, 2023 | 131 | -8 | -5.76% |
| Mar 31, 2022 | 139 | 1 | 0.72% |
| Mar 31, 2021 | 138 | 5 | 3.76% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 700 |
| Cellectis | 222 |
| Genfit | 188 |
| Innate Pharma | 174 |
| Transgene | 147 |
| DBV Technologies | 117 |
| Nanobiotix | 103 |
| Inventiva | 84 |
MedinCell News
- 4 months ago - Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults - Nasdaq
- 4 months ago - Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed - Nasdaq
- 1 year ago - Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia - Seeking Alpha